[4] The result is a GHRH-receptor agonist that survives slightly longer in circulation than the unmodified hormone while still producing the same fundamental action: stimulation of the somatotroph cells of the anterior pituitary to release GH in a pulsatile, physiologic pattern, which in turn raises IGF-1
PMCID: PMC3353819
NEJM 2024: EMA: Warning about sharp rise in illegal medicines sold in the EU, 3 September 2025: FDA: Certain bulk drug substances for use in compounding may present significant safety risks: USADA: BPC-157 Experimental Peptide Prohibited: Jastreboff AM et al
Sosne G, Qiu P, Goldstein AL, Wheater M
Sermorelin and semaglutide are two separate peptides with distinct mechanisms: sermorelin stimulates growth hormone secretion, while semaglutide activates GLP-1 receptors for metabolic regulation
Inject before bed, at least 2 hours after your last meal